The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is explored. Financial obstacles and customized treatments are discussed. The importance of precise timing for treatments is highlighted. Myelosuppression and new dosing ideas are brought up.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Clinical trial design’s role in optimizing treatment is mentioned, with examples of challenges in drug approval. The need for data confidence, stepwise treatment, and MRD monitoring are emphasized.